CD276 and prostate cancer: CD276, also known as B7-H3, is a type I transmembrane glycoprotein that overexpresses extensively in a variety of solid tumors, including breast cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, lung cancer, and prostate cancer, and is termed as a pan-solid tumor-related cell surface antigen.